Abstracts tagged "joint damage and rheumatoid arthritis (RA)"

Abstract Number: 2506 • 2018 ACR/ARHP Annual Meeting
The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only
Evo Alemao¹, Yogesh Saini², Ying Bao¹, Aarti Rao², Christine K Iannaccone³, Michael E Weinblatt³ and Nancy A. Shadick³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered a poor prognostic factor in RA and is a common extra-articular manifestation of RA. We estimated prevalence of…
Abstract Number: 1353 • 2017 ACR/ARHP Annual Meeting
Is Joint Damage Due to Secondary Osteoarthritis (OA) Clinically As Important As Inflammation in Contemporary Management of Rheumatoid Arthritis (RA)?
Theodore Pincus¹, Isabel Castrejón², Kathryn A. Gibson³ and Joel A Block², ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Liverpool Hospital, Sydney, Australia, Sydney, Australia
Background/Purpose: Measures to assess patients with rheumatoid arthritis (RA) reflect primarily inflammatory activity in patients who meet inclusion criteria for selection into clinical trials. However,…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…
Abstract Number: 450 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study
Rocio V. Gamboa-Cardenas^1,2, Manuel Ugarte-Gil³, Francisco Zevallos⁴, Mariela Medina⁴, Claudia Elera-Fitzcarrald⁴, Victor Pimentel-Quiroz⁴, Cristina Reategui-Sokolova⁴, Omar Sarmiento-Velasquez⁴, Zoila Rodriguez-Bellido⁴, José Alfaro⁴, Mariano Cucho-Venegas⁴, Cesar A. Pastor-Asurza⁴ and Risto Perich-Campos⁵, ¹Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, ²Universidad Nacional Mayor de San Marcos, Lima, Peru, ³Peru, GLADEL, Lima, Peru, ⁴Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru
Background/Purpose: Optimal management of Rheumatoid Arthritis (RA) based in identification of patients with risk factors for Joint Damage (JD) progression, is a main strategy, but…
Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Helena Enocsson¹, Alf Kastbom¹, Tanja Lukic¹, Christopher Sjöwall², Thomas Skogh¹ and Jonas Wetterö¹, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 1028 • 2017 ACR/ARHP Annual Meeting
Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA
Ricardo Segurado¹, Denis Shields¹, Rachel Knevel², Annette H.M. van der Helm-van Mil³, Tom W.J. Huizinga⁴ and Anthony G. Wilson⁵, ¹University College Dublin, Dublin, Ireland, ²Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁵UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is…
Abstract Number: 583 • 2016 ACR/ARHP Annual Meeting
Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients
Dongmei Sun¹, William H Robinson², Xiangqin Cui³, Vincent A. Laufer⁴, Maria I. Danila⁵, Richard J. Reynolds⁶, Chander Raman⁷, Stephanie Ledbetter⁸, Alexander Szalai⁹ and S. Louis Bridges Jr.⁹, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸1825 University Blvd., University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Serum anti-citrullinated proteins (ACPA, including anti-CCP antibodies) and rheumatoid factor (RF) are critical diagnostic markers for RA, and are associated with more severe radiographic…
Abstract Number: 644 • 2016 ACR/ARHP Annual Meeting
Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics
Kichul Shin¹, Seongjun Ha², Inkyung Jung³, Hyoun-Ah Kim⁴ and Shin-Seok Lee⁵, ¹Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ⁴Ajou University Hospital, Suwon, South Korea, ⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: High titers of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACCP) are poor prognostic factors for rheumatoid arthritis (RA) patients. Only few studies…
Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting
Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
María López-Lasanta¹, Antonio Julià¹, Joan Maymo², Benjamin Fernandez Gutierrez³, Inmaculada Ureña⁴, Francisco J. Blanco⁵, Juan D. Cañete⁶, Mercedes Alperi-López⁷, Alejandro Olivé⁸, Hector Corominas⁹, Jesús Tornero¹⁰, Alba Erra¹¹, Miriam Almirall¹², Nuria Palau¹³, Ana M. Ortiz Garcia¹⁴, Gabriela Avila¹³, Luis Rodriguez-Rodriguez¹⁵, Arnald Alonso¹, Raül Tortosa¹, Isidoro González-Alvaro¹⁶ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, Hospital del Mar, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁸Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹¹Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, ¹²Rheumatology Department, Hospital del Mar, Barcelona, Spain, ¹³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
Abstract Number: 104 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies SLC8A3 As a Susceptibility Locus for ACPA-Positive Rheumatoid Arthritis
Antonio Julià¹, Isidoro González-Alvaro², Antonio Fernandez-Nebro³, Francisco Blanco⁴, Benjamin Fernandez Gutierrez⁵, Antonio Gonzalez⁶, Juan D. Cañete⁷, Joan Maymo⁸, Mercedes Alperi-López⁹, Alejandro Olivé¹⁰, Hector Corominas¹¹, Víctor Martínez Taboada¹², Alba Erra¹³, Simon Sanchez Fernandez¹⁴, Arnald Alonso¹, María López-Lasanta¹, Raül Tortosa¹, S. Louis Bridges Jr.¹⁵, Jesús Tornero¹⁶ and Sara Marsal¹⁷, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ⁴Rheumatology Division, Fundación Profesor Novoa Santos, A Coruna, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶H. Clinico Universtiario de Santiago, Santiago de Compostela, Spain, ⁷Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, ⁸H del Mar, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹³CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹⁴Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, ¹⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹⁷Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) patients with serum anti-citrullinated peptide antibodies (ACPA) have a strong and specific genetic background. We performed a genome-wide association study (GWAS)…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 1573 • 2015 ACR/ARHP Annual Meeting
Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study
Yu Asanuma¹, Yuki Shimada², Yoshimi Aizaki¹, Kazuhiro Yokota¹, Noritsune Kouzu³, Yoshitake Takebayashi⁴, Hisashi Noma⁴, Shinichi Kawai⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Kouzu Orthopaedic Clinic, Chiba, Japan, ⁴The Institute of Statistical Mathematics, Tokyo, Japan, ⁵Div of Rheum/dept of Int Med, Toho Uni Sch of Med, Tokyo, Japan
Background/Purpose: Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local…
Abstract Number: 1582 • 2015 ACR/ARHP Annual Meeting
Joint Damage Associated with Loss of Body Mass in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada del Rincon², Daniel Battafarano³ and Agustin Escalante⁴, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁴Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Body mass index (BMI) is a predictor of long-term outcome in rheumatoid arthritis and has been associated with joint damage. Our objective was to examine…
Abstract Number: 3102 • 2015 ACR/ARHP Annual Meeting
Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy
Jon T. Giles¹, S. Louis Bridges Jr.², James R. O'Dell³, Stacey Cofield⁴, George Howard⁵, Jeffrey R. Curtis⁶ and Larry W. Moreland⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Higher levels of circulating adiponectin have been linked to radiographic progression in RA in observational studies, but never studied in the context of early…
Abstract Number: 1370 • 2014 ACR/ARHP Annual Meeting
The Association of Body Mass Index (BMI) and Radiographic Progression of Joint Disease in Rheumatoid Arthritis (RA)
Christine K. Iannaccone¹, Jing Cui², K P Liao³, Jonathan S. Coblyn³, Michael Weinblatt⁴ and Nancy A. Shadick⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Womens Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital/Harvard University, Cambridge, MA
Background/Purpose Previous studies suggest that lower BMI is associated with progression of radiographic joint damage in RA but little is known about the biological role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].